RAPT Therapeutics, Inc. (RAPT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“Rapt” or the “Company”) (NASDAQ: RAPT). Investors who purchased Rapt securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Rapt has violated federal securities laws.
On March 14, 2023, Rapt issued a press release in which the Company disclosed, among other items, that “[f]or our Phase 2b trial of RPT193 in atopic dermatitis, we now expect topline results in mid-2024 due to recent slower than expected patient enrollment as we did not see the seasonal uptick that we anticipated.” On news of the delay, Rapt’s stock price fell $5.00 per share, or 20.24%, to close at $19.70 per share on March 14, 2023.
If you are aware of any facts relating to this investigation or purchased Rapt shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.